ATE524196T1 - An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür - Google Patents

An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür

Info

Publication number
ATE524196T1
ATE524196T1 AT02801760T AT02801760T ATE524196T1 AT E524196 T1 ATE524196 T1 AT E524196T1 AT 02801760 T AT02801760 T AT 02801760T AT 02801760 T AT02801760 T AT 02801760T AT E524196 T1 ATE524196 T1 AT E524196T1
Authority
AT
Austria
Prior art keywords
cancer
associated antigen
antibodies binding
antigen
mpa7
Prior art date
Application number
AT02801760T
Other languages
English (en)
Inventor
Jennie Mather
Original Assignee
Macrogenics West Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics West Inc filed Critical Macrogenics West Inc
Application granted granted Critical
Publication of ATE524196T1 publication Critical patent/ATE524196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02801760T 2001-10-16 2002-10-16 An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür ATE524196T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32964401P 2001-10-16 2001-10-16
PCT/US2002/033116 WO2003032814A2 (en) 2001-10-16 2002-10-16 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE524196T1 true ATE524196T1 (de) 2011-09-15

Family

ID=23286361

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801760T ATE524196T1 (de) 2001-10-16 2002-10-16 An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür

Country Status (6)

Country Link
US (2) US7148038B2 (de)
EP (1) EP1441766B1 (de)
JP (1) JP4347694B2 (de)
AT (1) ATE524196T1 (de)
CA (1) CA2463927A1 (de)
WO (1) WO2003032814A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148038B2 (en) 2001-10-16 2006-12-12 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
US7264800B2 (en) * 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
UA81634C2 (ru) * 2002-07-18 2008-01-25 Хеликс Биофарма Корп. Фармацевтическая композиция уреазы для ингибирования роста раковых клеток и ее применение
US20050226873A1 (en) * 2003-09-30 2005-10-13 Del Priore Lucian V Medical devices and methods for modulating cell adhesion
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
EP1739173A1 (de) * 2004-03-29 2007-01-03 Medical & Biological Laboratories Co., Ltd. Kit zur diagnose von solidem krebs und medizin für die therapie von solidem krebs
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
CA2675521C (en) * 2007-01-22 2016-04-26 Raven Biotechnologies Human cancer stem cells
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
EP2542256B1 (de) 2010-03-04 2019-05-22 MacroGenics, Inc. Mit b7-h3 reagierende antikörper, immunologisch wirkende fragmente davon und verwendungen davon
AU2011286024B2 (en) 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2689787A1 (de) * 2010-09-03 2014-01-29 Stem Centrx, Inc. Neue Modulatoren und deren Verwendung
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
AU2011295715B9 (en) * 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
US8642951B2 (en) 2011-05-04 2014-02-04 Agilent Technologies, Inc. Device, system, and method for reflecting ions
BR112013029892A2 (pt) 2011-05-21 2016-12-20 Macrogenics Inc polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada
US9567402B2 (en) * 2013-03-14 2017-02-14 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate and other cancer cells
WO2015007887A1 (en) * 2013-07-19 2015-01-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of a ligand of hvem and an immunotoxin for use in therapy
WO2015085162A1 (en) 2013-12-05 2015-06-11 Rfemb Holdings, Llc Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb)
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
JP6730260B2 (ja) 2014-09-12 2020-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬
US11141216B2 (en) 2015-01-30 2021-10-12 Immunsys, Inc. Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
HUE068868T2 (hu) 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
KR20180108655A (ko) 2016-01-15 2018-10-04 알에프이엠비 홀딩스, 엘엘씨 암의 면역학적 치료
CN105462935B (zh) * 2016-01-20 2017-08-04 潘世扬 抗卵巢癌单克隆抗体及其应用
WO2018089829A1 (en) 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
CA3043277A1 (en) 2016-11-11 2018-05-17 The Regents Of The University Of California Anti-cd46 antibodies and methods of use
AU2018224094B2 (en) 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
KR20200098590A (ko) 2017-12-12 2020-08-20 마크로제닉스, 인크. 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
JP7337079B2 (ja) 2018-02-15 2023-09-01 マクロジェニクス，インコーポレーテッド 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用
EP4192511A1 (de) 2020-08-07 2023-06-14 Fortis Therapeutics, Inc. Gegen cd46 gerichtete immunkonjugate und verfahren zur verwendung davon

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5496550A (en) 1986-08-14 1996-03-05 Chilwalner Method of reducing the output of Eimeria oocysts from a newborn chick
EP0300213A1 (de) 1987-06-22 1989-01-25 Hexal-Pharma Gentechnik GmbH & Co. KG Virale, immunogen wirksame Peptidpartikel von Hepatitis A
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1991002002A1 (en) 1989-07-21 1991-02-21 Washington University Recombinantly produced human membrane cofactor protein (mcp)
US5514787A (en) 1989-07-21 1996-05-07 Washington University DNA sequences encoding human membrane cofactor protein (MCP)
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5846715A (en) 1990-05-11 1998-12-08 The Austin Research Institute CD46 variants
EP0519596B1 (de) 1991-05-17 2005-02-23 Merck & Co. Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
JP3919830B2 (ja) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
CA2153165C (en) 1993-01-14 2003-05-06 Hiroaki Maeda Recombinant anti-hiv antibody and process for preparing the same
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5665570A (en) 1994-02-10 1997-09-09 Takeda Chemical Industries, Ltd. Antibody-encoding recombinant DNA and its use
WO1997035016A1 (en) 1996-03-18 1997-09-25 Novo Nordisk Biotech Inc Polypeptides having phytase activity and nucleic acids encoding same
KR19990072201A (ko) 1996-10-18 1999-09-27 무타이 마사히꼬 로타바이러스 항원, 로타바이러스 감염증에 대한백신 및 진단제와 항원 제조방법
AU6150498A (en) * 1997-02-07 1998-08-26 Wistar Institute, The Methods and compositions for the inhibition of interleukin-12 production
CN1044092C (zh) * 1997-02-26 1999-07-14 上海医科大学 抗原－抗体－重组dna复合型疫苗
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2001088537A1 (en) 2000-05-12 2001-11-22 Martens Mark G Diagnostic method for screening complement regulatory protein levels
US20030129677A1 (en) * 2000-05-12 2003-07-10 Martens Mark G. Diagnostic method for screening complement regulatory protein levels
EP1184458A1 (de) 2000-08-28 2002-03-06 U-BISys B.V. Unterschiedlich exprimierte CD46 Epitope, proteinartige Moleküle die fähig sind daran zu binden, und deren Verwendungen
US20020115065A1 (en) * 2000-08-28 2002-08-22 Ton Logtenberg Differentially expressed epitopes and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7148038B2 (en) * 2001-10-16 2006-12-12 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
MXPA04011828A (es) * 2002-05-30 2005-11-23 Raven Biotechnologies Inc Modelo animal para toxicologia y prediccion de dosis.
EP1560597A4 (de) * 2002-10-29 2007-06-27 Pharmacia Corp Differentiell ausgedrückte krebsgene, dabei kodierte polypeptide und verfahren zu ihrer verwendung
AU2005313971B2 (en) * 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer

Also Published As

Publication number Publication date
JP4347694B2 (ja) 2009-10-21
EP1441766B1 (de) 2011-09-14
US20030108966A1 (en) 2003-06-12
JP2005511525A (ja) 2005-04-28
WO2003032814A3 (en) 2003-09-12
WO2003032814A2 (en) 2003-04-24
CA2463927A1 (en) 2003-04-24
HK1064621A1 (en) 2005-02-04
US7148038B2 (en) 2006-12-12
EP1441766A4 (de) 2006-03-08
US20070128202A1 (en) 2007-06-07
EP1441766A2 (de) 2004-08-04
US7744878B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
ATE524196T1 (de) An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
NO20074474L (no) Antistoffer som binder til EPHA2 og fremgangsmate for anvendelse derav
WO2003024191A3 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
DE69433663D1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
DE602006013029D1 (de) Anti-egfr-antikörper
TR200202799T3 (tr) AB peptidini sekanslayan insanlaştırılmış antikorlar
PH12022550195A1 (en) Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
TW200510459A (en) RG1 antibodies and uses thereof
DE69940436D1 (de) Prostata stammzellantigen (psca) und dessen verwendungen
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
ATE303161T1 (de) Humanisierung von anti-carcinoembryonalen antigen anti-idiotypischen antikörper und dessen verwendung als tumorvakzin und zur markierung
MXPA06010673A (es) Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
DE60224346D1 (de) Monoklonales Antikörper gegen das HCV Kernantigen
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
WO2004043239A3 (en) Antigen pipa and antibodies that bind thereto
WO2003064593A3 (en) Antigen panels and methods of using the same
WO2002072008A3 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
WO2004101762A3 (en) Detection and treatment of cancers of the colon
WO2003024302A3 (en) Detection and treatment of cancers of breast

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties